Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya4685710.26442/00403660.2020.09.000558ReviewsОбзорыReview ArticleHypertrophic cardiomyopathy in elderly: causes, diagnostic and treatment approachesГипертрофическая кардиомиопатия у пожилых: причины, диагностика, лечениеhttps://orcid.org/0000-0003-2373-1183ChumakovaO. S.ЧумаковаОльга Сергеевна
Russian Federation

к.м.н., доц. каф. терапии, кардиологии и функциональной диагностики с курсом нефрологии

chumakovaolga@bk.ruCentral State Medical Academy of the President of the Russian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ1410202092963691310202013102020Copyright ©; 2020, Consilium MedicumCopyright ©; 2020, ООО "Консилиум Медикум"2020Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/46857

Hypertrophic cardiomyopathy is the most common inherited heart disorder with high clinical heterogeneity. Every fifth patient is older than 60 years at first diagnosis. This review discusses the possible causes for the late onset of hypertrophic cardiomyopathy, the diagnostic and treatment approaches in the elderly.

Гипертрофическая кардиомиопатия (ГКМП) – самая распространенная наследственная патология сердца с высокой клинической гетерогенностью. У каждого пятого больного диагноз впервые устанавливается в возрасте старше 60 лет. В обзоре обсуждаются возможные причины позднего дебюта гипертрофической кардиомиопатии, особенности диагностики и лечения этого заболевания у пожилых больных.

hypertrophic cardiomyopathyelderlygeneticsdiagnosticstreatmentгипертрофическая кардиомиопатияпожилыегенетикадиагностикалечениеGrant from the Russian Science Foundation No. 20-15-00353Грант Российского научного фонда №20-15-00353Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi: 10.1016/j.jacc.2015.01.019Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121(7):749-70. doi: 10.1161/CIRCRESAHA.117.311059Maron BJ, Harris KM, Spirito P, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-25. doi: 10.1161/CIRCULATIONAHA.105.583500Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973;2(7844):1462-7. doi: 10.1016/s0140-6736(73)92730-xCharron P, Elliott PM, Gimeno JR, et al.; EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39(20):1784-93. doi: 10.1093/eurheartj/ehx819Maron BJ, Rowin EJ, Casey SA, et al. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016;117(3):434-5. doi: 10.1016/j.amjcard.2015.11.013Maron BJ, Casey SA, Haas TS, et al. Hypertrophic Cardiomyopathy With Longevity to 90 Years or Older. Am J Cardiol. 2012;109(9):1341-7. doi: 10.1016/j.amjcard.2011Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-98. doi: 10.1161/CIRCULATIONAHA.117.033200Maron BJ, Casey SA, Maron MS. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. Shaped by 50 Years of Clinical Research and Practice. JAMA Cardiol. 2016;1(1):98-105. doi: 10.1001/jamacardio.2015.0354Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiol. 2019; p. E1-E8. doi: 10.1001/jamacardio.2019.4534Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al. A Molecular Basis for Familial Hypertrophic Cardiomyopathy: A beta Cardiac Myosin Heavy Chain Gene Missense Mutation. Cell. 1990;62:999-1006. doi: 10.1016/0092-8674(90)90274-iMaron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(15):1978-86. doi: 10.1016/j.jacc.2019.01.061Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2):e001620. doi: 10.1161/CIRCGENETICS.116.001620Anan R, Niimura H, Takenaka T, et al. Mutations in the genes for sarcomeric proteins in Japanese patients with onset sporadic hypertrophic cardiomyopathy after age 40 years. Am J Cardiol. 2007;99(12):1750-4. doi: 10.1016/j.amjcard.2007.01.066Hirota T, Kitaoka H, Kubo T, et al. Morphologic characteristics of hypertrophic cardiomyopathy of the elderly with cardiac myosin-binding protein C gene mutations. Circ J. 2006;70(7):875-9. doi: 10.1253/circj.70.875Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89(6):727-37. doi: 10.1016/j.mayocp.2014.01.025Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-8. doi: 10.1038/gim.2014.205Bagnall RD, Ingles J, Dinger ME, et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2018;72(4):419-29. doi: 10.1016/j.jacc.2018.04.078Van Driest SL AM, Ommen SR, Shakur R, et al. Prevalence and severity of «benign» mutations in the beta-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002;106(24):3085-90. doi: 10.1161/01.cir.0000042675.59901.14Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, et al. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart. 2010;96(24):1980-4. doi: 10.1136/hrt.2010.200402Jansweijer JA, van Spaendonck-Zwarts KY, Tanck MWT, et al. Heritability in genetic heart disease: the role of genetic background. Open Heart. 2019;6(1):e000929. doi: 10.1136/openhrt-2018-000929Cerrone M, Remme CA, Tadros R, et al. Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders. Circulation. 2019;140(7):595-610. doi: 10.1161/CIRCULATIONAHA.118.035954Li L, Bainbridge MN, Tan Y, et al. A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder. Circ Res. 2017;120(7):1084-90. doi: 10.1161/CIRCRESAHA.116.310559Burns C, Bagnall RD, Lam L, et al. Multiple Gene Variants in Hypertrophic Cardiomyopathy in the Era of Next-Generation Sequencing. Circ Cardiovasc Genet. 2017;10(4):e001666. doi: 10.1161/CIRCGENETICS.116.001666Mouton JM, van der Merwe L, Goosen A, et al. MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients. Hum Genet. 2016;135(5):477-83. doi: 10.1007/s00439-016-1649-7Wooten EC, Hebl VB, Wolf MJ, et al. Formin Homology 2 Domain Containing 3 (FHOD3) Variants Associated with Hypertrophic Cardiomyopathy. Circ Cardiovasc Genet. 2013;6(1):10-8. doi: 10.1161/CIRCGENETICS.112.965277Perkins MJ Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J. 2005;26:2457-62. doi: 10.1093/eurheartj/ehi438Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87:270-5. doi: 10.1136/heart.87.3.270Kolder IC, Michels M, Christiaans I, et al. The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum Genet. 2012;20(10):1071-7. doi: 10.1038/ejhg.2012.48Axelsson A, Iversen K, Vejlstrup N, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-31. doi: 10.1016/S2213-8587(14)70241-4Maron MS, Chan RH, Kapur NK, et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018;131(7):837-41. doi: 10.1016/j.amjmed.2018.02.025Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81(4):459-67. doi: 10.4065/81.4.459Kubo T, Kitaoka H, Okawa M, et al. Hypertrophic cardiomyopathy in the elderly. Geriatr Gerontol Int. 2010;10(1):9-16. doi: 10.1111/j.1447-0594.2009.00572.xLever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation. 1989;79(3):580-9. doi: 10.1161/01.cir.79.3.580Canepa M, Malti O, David M, et al. Prevalence, Clinical Correlates and Functional Impact of Subaortic Ventricular Septal Bulge (From the Baltimore Longitudinal Study of Aging). Am J Cardiol. 2014;114(5):796-802. doi: 10.1016/j.amjcard.2014.05.068Ranasinghe I, Ayoub C, Cheruvu C, et al. Isolated hypertrophy of the basal ventricular septum: characteristics of patients with and without outflow tract obstruction. Int J Cardiol. 2014;173(3):487-93. doi: 10.1016/j.ijcard.2014.03.078Turer AT, Samad Z, Valente AM, et al. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(2):131-9. doi: 10.1093/ejechocard/jeq163Bos JM, Will M, Ommen S, et al. Yield of genetic testing among patients with hypertrophic cardiomyopathy diagnosed after 65 years of age. JACC. 2013;61(10):E1305. doi: 10.1016/S0735-1097(13)61305-4Hata Y, Ichimata S, Yamaguchi Y, et al. Clinicopathological and Genetic Profiles of Cases with Myocyte Disarray - Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. J Clin Med. 2019;8(4):463. doi: 10.3390/jcm8040463Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature and typing. Cardiovascular Pathology. 2015;24(6):343-50. doi: 10.1016/j.carpath.2015.07.008Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2019:S0167-5273(19)30935-0. doi: 10.1016/j.ijcard.2019.07.051González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. doi: 10.1093/eurheartj/ehv338Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31-40. doi: 10.1086/504601Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi: 10.1016/j.jacc.2007.06.062Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407-11. doi: 10.1161/01.cir.0000012626.81324.38Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-18. doi: 10.1002/ejhf.541Leong KMW, Chow JJ, Ng FS, et al. Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;121(3):349-55. doi: 10.1016/j.amjcard.2017.10.027Ушкалова Е.А. Зырянов С.К., Затолочина К.Э. и др. Применение антиаритмических средств у пожилых пациентов. Препараты I и II класса по классификации Вогана-Вильямса. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):471-8 [Ushkalova EA, Zyryanov SK, Zatolochina KE, et al. Antiarrhythmic drugs use in elderly patients. Vaughan Williams class I and II drugs. Rational Pharmacotherapy in Cardiology. 2016;12(4):471-8 (In Russ.)]. doi: 10.20996/1819-6446-2016-12-4-471-478Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783-831. doi: 10.1161/CIR.0b013e318223e2bdLiebregts M, Steggerda RC, Vriesendorp PA, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2016;9(5):463-9. doi: 10.1016/j.jcin.2015.11.036Kimmelstiel C, Zisa DC, Kuttab JS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019;12(7):e007673. doi: 10.1161/CIRCINTERVENTIONS.118.007673Maron BJ, Rowin EJ, Casey SA, et al. Risk Strati cation and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age. Circulation. 2013;127(5):585-93. doi: 10.1161/CIRCULATIONAHA.112.136085Guttmann OP, Rahman MS, O’Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465-72. doi: 10.1136/heartjnl-2013-304276Guttmann OP, Pavlou M, O’Mahony C, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017;103(9):672-8. doi: 10.1136/heartjnl-2016-309672Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017;136(25):2420-36. doi: 10.1161/CIRCULATIONAHA.117.029267Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24(2):189-97. doi: 10.1007/s10741-018-9752-6